Vanden Heuvel J P, Sterchele P F, Nesbit D J, Peterson R E
Environmental Toxicology Center, University of Wisconsin, Madison 53706.
Biochim Biophys Acta. 1993 Jun 6;1177(2):183-90. doi: 10.1016/0167-4889(93)90039-r.
Acyl-CoA binding protein (ACBP) and fatty acid binding protein (FABP) are important intracellular lipid binding proteins. The purpose of the present experiments was to test the hypothesis that peroxisome proliferators induce ACBP in rat hepatocytes as has been shown previously for FABP. The effects of two structurally dissimilar peroxisome proliferators perfluorodecanoic acid (PFDA) and clofibric acid (CPIB) were examined in primary rat hepatocyte cultures in a chemically defined media. Both compounds alter lipid metabolism in primary rat hepatocytes in a similar fashion, although PFDA is more potent than CPIB at inducing peroxisomal beta-oxidation. In addition, PFDA and CPIB compete with long-chain fatty acids for binding to FABP but do not compete with long-chain acyl-CoA esters for binding to ACBP. The concentration of ACBP and FABP was increased in peroxisome proliferator-treated hepatocytes relative to vehicle controls within 48 h of treatment. Evidence is given to support increases in ACBP and FABP mRNA being the cause of the increased protein levels by peroxisome proliferators. In addition, the peroxisome proliferators PFDA, perfluorooctanoic acid and ciprofibrate induced hepatic ACBP following in vivo administration to rats indicating that this phenomena is not exclusive to in vitro systems. Therefore, ACBP appears to be a member of the peroxisome proliferator loci, a group of lipid metabolizing proteins, including FABP, which are regulated by peroxisome proliferators such as fibric acids and perfluorinated fatty acids.
酰基辅酶A结合蛋白(ACBP)和脂肪酸结合蛋白(FABP)是重要的细胞内脂质结合蛋白。本实验的目的是验证如下假说:过氧化物酶体增殖剂可诱导大鼠肝细胞中的ACBP,正如之前所表明的,它也能诱导FABP。在化学成分明确的培养基中,对原代大鼠肝细胞培养物检测了两种结构不同的过氧化物酶体增殖剂全氟癸酸(PFDA)和氯贝酸(CPIB)的作用。尽管在诱导过氧化物酶体β-氧化方面PFDA比CPIB更有效,但两种化合物均以相似的方式改变原代大鼠肝细胞中的脂质代谢。此外,PFDA和CPIB与长链脂肪酸竞争结合FABP,但不与长链酰基辅酶A酯竞争结合ACBP。与溶剂对照相比,在处理48小时内,过氧化物酶体增殖剂处理的肝细胞中ACBP和FABP的浓度增加。有证据支持ACBP和FABP mRNA的增加是过氧化物酶体增殖剂导致蛋白质水平升高的原因。此外,过氧化物酶体增殖剂PFDA、全氟辛酸和环丙贝特在对大鼠进行体内给药后可诱导肝脏ACBP,这表明这种现象并非体外系统所特有。因此,ACBP似乎是过氧化物酶体增殖剂作用位点的成员,过氧化物酶体增殖剂作用位点是一组脂质代谢蛋白,包括FABP,它们受纤维酸和全氟脂肪酸等过氧化物酶体增殖剂的调节。